Full Press Release Details
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission.
BIIB
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
Key Takeaway: Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
Price reaction · baseline $250.33 (2023-12-18 close) · hit after-hours · clean, no other BIIB news in the window
day 0 close · peak
+0.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis